Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Rapid Test Uses Mobile Phone to Identify Severe Imported Malaria Within Minutes

By LabMedica International staff writers
Posted on 02 Feb 2026

Malaria remains the deadliest parasitic disease worldwide, and although it is not endemic in countries such as Spain, imported cases are diagnosed every year in travelers returning from high-risk regions. More...

These patients can deteriorate quickly, yet early symptoms are often nonspecific, making it difficult to identify who will develop severe malaria. This challenge is especially acute in non-endemic settings, where clinical experience is limited. Researchers have now developed a rapid, low-cost approach that can both detect malaria and predict disease severity using a mobile phone.

Researchers at the Universitat Rovira i Virgili (URV, Catalonia, Spain) and Barcelona Institute for Global Health (ISGlobal, Barcelona, Spain) have developed a system that combines standard malaria rapid diagnostic tests with smartphone-based video analysis to extract quantitative information from test strips. The approach focuses on two parasite-derived biomarkers: PfHRP2, a protein specific to Plasmodium falciparum, and pan-lactate dehydrogenase (pan-pLDH), an enzyme present across Plasmodium species. By analyzing how these markers behave in lateral flow assays, the system delivers results in under six minutes without requiring complex laboratory infrastructure

Using laboratory immunoassays and rapid tests, the team compared the performance of PfHRP2 and pan-pLDH for malaria diagnosis and severity prediction. PfHRP2 proved highly accurate for confirming infection, particularly for P. falciparum. In contrast, pan-pLDH showed strong potential to identify patients at risk of severe malaria, even when measured with simple rapid tests.

The study, published in Biosensors and Bioelectronics, demonstrated that smartphone-based video analysis could reliably quantify these biomarkers. This allowed the researchers to distinguish not only infected from non-infected individuals, but also patients more likely to progress to severe disease.

So far, the strategy has been validated in non-endemic settings, where malaria is rare but often severe and diagnostic resources are concentrated in specialized centers. The researchers believe the approach could eventually be adapted for endemic regions as well, given its low cost, speed, and reliance on widely available mobile phone technology.

However, further validation will be needed to account for epidemiological and clinical differences in those settings. The team is now working to confirm the findings in larger patient cohorts and real-world clinical environments. Their goal is for smartphone-assisted rapid tests to become a routine tool for early identification and risk stratification of imported malaria cases.

Related Links:
URV
ISGlobal


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.